DE69825594D1 - Screening-Methode unter Verwendung des FREAC-11 Transkriptionsfaktors - Google Patents

Screening-Methode unter Verwendung des FREAC-11 Transkriptionsfaktors

Info

Publication number
DE69825594D1
DE69825594D1 DE69825594T DE69825594T DE69825594D1 DE 69825594 D1 DE69825594 D1 DE 69825594D1 DE 69825594 T DE69825594 T DE 69825594T DE 69825594 T DE69825594 T DE 69825594T DE 69825594 D1 DE69825594 D1 DE 69825594D1
Authority
DE
Germany
Prior art keywords
freac
transcription factor
relates
screening method
adipose tissue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69825594T
Other languages
English (en)
Other versions
DE69825594T2 (de
Inventor
Sven Enerbaeck
Peter Carlsson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Swedish Orphan Biovitrum AB
Original Assignee
Biovitrum AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biovitrum AB filed Critical Biovitrum AB
Application granted granted Critical
Publication of DE69825594D1 publication Critical patent/DE69825594D1/de
Publication of DE69825594T2 publication Critical patent/DE69825594T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Nutrition Science (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Developing Agents For Electrophotography (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Peptides Or Proteins (AREA)
DE69825594T 1997-05-26 1998-05-26 Screening-Methode unter Verwendung des FREAC-11 Transkriptionsfaktors Expired - Fee Related DE69825594T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9701963A SE9701963D0 (sv) 1997-05-26 1997-05-26 Novel transcription factor
SE9701963 1997-05-26
PCT/SE1998/000989 WO1998054216A1 (en) 1997-05-26 1998-05-26 Gene and amino acid sequences for novel transcription factor

Publications (2)

Publication Number Publication Date
DE69825594D1 true DE69825594D1 (de) 2004-09-16
DE69825594T2 DE69825594T2 (de) 2005-09-15

Family

ID=20407085

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69825594T Expired - Fee Related DE69825594T2 (de) 1997-05-26 1998-05-26 Screening-Methode unter Verwendung des FREAC-11 Transkriptionsfaktors

Country Status (10)

Country Link
EP (1) EP1003776B1 (de)
JP (1) JP2002503102A (de)
AT (1) ATE273321T1 (de)
AU (1) AU742500B2 (de)
CA (1) CA2291484A1 (de)
DE (1) DE69825594T2 (de)
NO (1) NO324817B1 (de)
NZ (1) NZ501804A (de)
SE (1) SE9701963D0 (de)
WO (1) WO1998054216A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE304552T1 (de) * 2000-02-18 2005-09-15 Leangene Ab Methoden zur identifizierung von zusammensetzungen, die für die behandlung von fettleibigkeit nützlich sind, unter verwendung von foxc2
WO2002027008A1 (en) * 2000-09-26 2002-04-04 Biovitrum Ab Promoter sequences
EP1468017A1 (de) * 2002-01-29 2004-10-20 Biovitrum Ab Komplex eines humanen foxc2 proteins und eines mit foxc2 wechselwirkenden proteins
US7955795B2 (en) 2003-06-06 2011-06-07 Qiagen Gmbh Method of whole genome amplification with reduced artifact production
WO2005099363A2 (en) 2004-03-26 2005-10-27 Whitehead Institute For Biomedical Research Methods of diagnosing, preventing and treating cancer metastasis
EP1762627A1 (de) 2005-09-09 2007-03-14 Qiagen GmbH Verfahren zur Aktivierung einer Nukleinsäure für eine Polymerase-Reaktion

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5563036A (en) * 1994-04-29 1996-10-08 Tularik, Inc. Transcription factor-DNA binding assay

Also Published As

Publication number Publication date
NO995786D0 (no) 1999-11-25
AU7682698A (en) 1998-12-30
EP1003776A1 (de) 2000-05-31
CA2291484A1 (en) 1998-12-03
EP1003776B1 (de) 2004-08-11
NZ501804A (en) 2002-06-28
NO995786L (no) 2000-01-25
SE9701963D0 (sv) 1997-05-26
AU742500B2 (en) 2002-01-03
ATE273321T1 (de) 2004-08-15
NO324817B1 (no) 2007-12-10
DE69825594T2 (de) 2005-09-15
WO1998054216A1 (en) 1998-12-03
JP2002503102A (ja) 2002-01-29

Similar Documents

Publication Publication Date Title
Barnier et al. Mouse 89 kD heat shock protein: two polypeptides with distinct developmental regulation
ATE449850T1 (de) Mutanten von flt3-l und ihre verwendungen
PT98357A (pt) Baculovirus modificado,processo para a sua preparacao e vectores de expressao obtidos a partir do dito baculovirus
BR0207325A (pt) Métodos terapêuticos para doenças associadas com expressão diminuìda de gene de aop-1 ou aop-1
DE60025037D1 (de) "functional genomics" unter verwendung von zink finger proteinen
DE69635609D1 (de) Nukleinsäure enthaltende zusammensetzung, herstellung und verwendung
AU4929701A (en) Whole-body optical imaging of gene expression and uses thereof
BR9908018A (pt) Adenovìrus modificado contendo uma proteìna de substituição de fibra
ATE404217T1 (de) Therapie mit lipoproteinlipase (lpl) variant
ATE273321T1 (de) Screening-methode unter verwendung des freac-11 transkriptionsfaktors
Bosserhoff et al. Establishing the protein MIA (melanoma inhibitory activity) as a marker for chondrocyte differentiation
EA200100583A1 (ru) Композиции, содержащие лактадгерин или его варианты, и способы их использования
ATE174629T1 (de) Herstellung von proteinen mittels protein 7b2
ATE364087T1 (de) Regulierung der expression von eer-7, ein mitglied der lysyl oxidase genfamilie, durch oestrogenrezeptoren
FR2744455B1 (fr) Nouvelles sequences d'acides nucleiques de la famille des facteurs suppresseurs de tumeurs, produits d'expression correspondants et leurs applications
ATE305037T1 (de) Peptide, die fähig sind die sh3-domäne des gap- proteins zu binden, ihre kodierende dns, ihre zubereitung und verwendung
DK0773290T3 (da) Hidtil ukendt LDL-receptoranalog-protein og det gen, der koder derfor
PT815233E (pt) NOVAS CITOCINAS AVIÁRIAS E SEQUjNCIAS GENÉTICAS QUE AS CODIFICAM
BR9712767A (pt) Expressão especìfica para tecido de proteìna de retinoblastoma
DE69613685D1 (de) D-aminosäure-oxidase kodierendes dns-fragment
Balic et al. Mineralization and expression of Col1a1-3.6 GFP transgene in primary dental pulp culture
DE69916829D1 (de) Genetisch veränderte fibroblasten und ihre verwendung
SE9803958D0 (sv) Method for screening
WO2003016343A3 (en) USE OF αCP1, αCP2, AND HUR FOR MODULATING GENE EXPRESSION AND INDUCING ANGIOGENESIS
HUP9901346A2 (hu) Deltap62 polipeptid és variánsai, ezeket kódoló nukleinsav-szekvenciák és felhasználásuk

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee